Related Experiment Video
Updated: Jun 17, 2026
10:25
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
Published on: February 19, 2019
11.6K
Hepatitis B Before and After Hepatocellular Carcinoma
Murat Harputluoglu1, Brian I Carr2
1Department of Gastroenterology and Transplant Hepatology, Faculty of Medicine, Liver Transplant Institute, Inonu University, Malatya, Turkey. mharputluoglu@hotmail.com.
Journal of Gastrointestinal Cancer
|November 11, 2021
Summary
Hepatitis B virus (HBV) significantly contributes to liver cancer (HCC), particularly in Eastern countries. Vaccination and antiviral treatments like TDF and ETV are crucial for preventing and managing HBV-associated HCC.
Area of Science:
- Hepatology
- Oncology
- Infectious Diseases
Background:
- Hepatitis B virus (HBV) is a primary cause of hepatocellular carcinoma (HCC), especially prevalent in Eastern regions.
- Understanding the HBV-HCC relationship is vital for public health strategies.
Purpose of the Study:
- To elucidate the intricate relationship between HBV infection and HCC development.
- To evaluate the efficacy of prevention and treatment strategies in reducing HCC incidence and improving patient outcomes.
Main Methods:
- This review synthesizes current scientific literature on HBV, HCC, and their management.
- Key prevention strategies including vaccination and treatment modalities like antivirals are analyzed.
Main Results:
- Hepatitis B vaccination is paramount in preventing HBV-associated HCC.
- Antiviral therapies, including tenofovir disoproxil fumarate (TDF) and entecavir (ETV), effectively suppress HBV viral load, thereby preventing HCC development and recurrence post-treatment.
- Tenofovir alafenamide (TAF) shows promise, though further data is needed.
Conclusions:
- Comprehensive HBV prevention and treatment are essential for mitigating HCC burden.
- Vaccination and effective antiviral therapy are cornerstones in the fight against HBV-induced liver cancer.
